Shanghai MicroPort Endovascular MedTech Co (688016) Fair Value & Analysis
Healthcare · CN · Market cap 11.2B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price +4.9% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (¥73.36 to ¥132.44) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥79.81 – ¥293.90 · fair‑value band ¥73.36 – ¥132.44 · the ¥94.20 price screens below the ¥100.52 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Shanghai MicroPort Endovascular MedTech Co (688016) currently trades at ¥94.20, while our model-based Fair Value estimate is ¥100.52, implying the stock looks roughly 6.7% fairly valued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Shanghai MicroPort Endovascular MedTech Co generated revenue of 1.4B CNY at a net margin of 42.4%. Revenue grew 11.5% year over year. It earns a return on equity of 14.3%. The balance sheet holds a net cash position of 2.1B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥73.36 (bear case) to ¥132.44 (bull case); at ¥94.20, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 7%, 688016 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥159.46) versus Asset-Based (¥21.65). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally.
Full company description
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai MicroPort Endovascular MedTech Co reported revenue of ¥1.4B in FY2025 versus ¥685M in FY2021, a compound +18.5%/yr. Reported net income was ¥563M in FY2025, compounding +15.6%/yr from FY2021.
Watch 688016: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Shanghai MicroPort Endovascular MedTech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai MicroPort Endovascular MedTech Co (688016) overvalued or undervalued?
What is the fair value of 688016?
What is the quality score of 688016?
What is the revenue of Shanghai MicroPort Endovascular MedTech Co (688016)?
What is the net profit margin of 688016?
Does Shanghai MicroPort Endovascular MedTech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai MicroPort Endovascular MedTech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.